Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-R-Immune Glioma: Upfront Nivolumab in RRD-HGG
NCT06519682Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of nivolumab in glioblastoma (GBM) (2 arms). Primary endpoint: Radiation-free survival at 2 years. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06519682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519682.